trial · primary record
Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
Acute Myeloid Leukemia
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 10 |
| Primary completion | 2028-12-31 |
| Primary endpoint | percentage of patients with treatment related adverse effect |
| Registry ID | NCT03222674 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:32.503Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03222674
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.